Mihaljevic AL, Friess H, Schuhmacher C (2013) Clinical trials in gastric cancer and the future. J Surg Oncol 107:289-297. doi:10.1002/jso.23120Mihaljevic AL, Friess H, Schuhmacher C (2013) Clinical trials in gastric cancer and the future. J Surg Oncol 107(3):289-297. doi:10. 1002/...
(A) Cases that have an important clinical impact: 1) Remarkable effects of a new therapy for gastric cancer; 2) Previously unreported adverse events in treatments for gastric cancer; 3) Novel suggestions or pitfalls in diagnosing gastric cancer; (B) Cases that may provide significant clues to ...
Thereafter, additional benefit of trastuzumab combined with a cisplatin and either fluorouracil or capecitabine regimen against HER2-positive gastric cancer has been confirmed from the results of international clinical trials (ToGA study). Becasue combination of S-1 and cisplatin is a standard therapy ...
The treatment landscape of gastric cancer has evolved significantly in the past few years, with the emergence of new immunotherapy and targeted therapies for patients at various stages of the disease (Fig.1). In this review, we systematically summarize the pivotal clinical trials in GC treatment a...
The treatment landscape of gastric cancer has evolved significantly in the past few years, with the emergence of new immunotherapy and targeted therapies for patients at various stages of the disease (Fig.1). In this review, we systematically summarize the pivotal clinical trials in GC treatment ...
and postoperative chemotherapy. Repeat analysis of ctDNA during treatment can also track changes in tumor genomic profiles [26]. Molecular heterogeneity is a significant challenge in biomarker-based clinical trials for cancer patients [109]. Still, ctDNA analysis can help to avoid false negative resu...
This letter is intended to arouse your interest in a recent review of comprehensive scientometrics and clinical trials on immunotherapy for gastric cancer(GC).Our study reviews recent advances in immunotherapy in the field of GC and highlights its new prospects as a treatment for GC.Our research ...
43. Although more than 10 IGF/IGF1R inhibitors have entered clinical trials44, many large clinical trials involving patients with non-small-cell lung cancer, breast cancer, and pancreatic cancer failed to show significant clinical benefit45,46,47. However, even among these unsuccessful trials, ...
FDA Clears NDA for Novel CDH17 CAR T-Cell Therapy in Advanced GI Cancer Hayley Virgil November 9th 2023 CHM 2101 will be assessed as part of a phase 1A/B clinical study in a population of patients diagnosed with advanced colorectal cancer, gastric cancer, and neuroendocrine cancer. CMG901 Sh...
[14]Lordick F,Carneiro F,Cascinu S,et al.Gastric cancer:ESMO Clinical Practice Guideline for diagnosis,treatment and follow-up.Ann Oncol.2022 Jul 29:S0923-7534(22)01851-8. [15]Shitara K,Bang YJ,Iwasa S,et al...